More on Albany Molecular Research's (AMRI) Q1: Contract revenue and margins rise 9% and 19% Y/Y...

|About: Albany Molecular Research, ... (AMRI)|By:, SA News Editor

More on Albany Molecular Research's (AMRI) Q1: Contract revenue and margins rise 9% and 19% Y/Y respectively with the latter driven by improvements in the performance of the discovery and large scale manufacturing segments. The company reaffirms its FY13 revenue guidance (~12% growth) and ups its EPS outlook to $0.52-0.65 per share. (PR)